文献速递细菌感染、耐药与抗菌药物

不同剂量吸入噬菌体疗法对小鼠铜绿假单胞菌肺部感染的影响

The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice.
PubMed 文献 · Clin Microbiol Infect · 2022-02-03

在中性粒细胞减少BALB/c小鼠铜绿假单胞菌肺部感染模型中,感染后2小时经气道给予靶向铜绿假单胞菌的噬菌体PEV31三个剂量或磷酸缓冲盐溶液。感染后24小时,各噬菌体治疗组肺部细菌载量均显著下降1.3-1.9 log10,与给药剂量无关;噬菌体复制程度与剂量负相关,噬菌体耐药亚群随剂量增加而增多。

要点

  • 感染后24小时,三个噬菌体治疗组肺部细菌载量均下降1.3-1.9 log10,与剂量无关。
  • 噬菌体复制程度与给药剂量负相关,A、B、C组滴度分别增加6.2、2.7、9 log10。
  • 肺部匀浆中噬菌体耐药亚群随剂量增加:A组30%、B组74%、C组91%。

核心结论

  • 本研究提供了吸入噬菌体疗法的剂量-反应效应,可能为人类铜绿假单胞菌呼吸道感染的剂量选择提供指导。

研究设计与样本

  • 中性粒细胞减少BALB/c小鼠经气管接种多重耐药铜绿假单胞菌2×10^4菌落形成单位,感染后2小时分别给予PEV31三个剂量或磷酸缓冲盐溶液。
  • PEV31剂量为7.5×10^4(A组)、5×10^6(B组)、5×10^8(C组)空斑形成单位。
  • 感染后2小时和24小时处死小鼠(n=5-7),收集肺、肾、脾、肝、支气管肺泡灌洗液和血液进行细菌和噬菌体计数。

主要发现

  • 感染后24小时,所有噬菌体治疗组肺部细菌载量均显著下降1.3-1.9 log10,与给药剂量无关。
  • 噬菌体复制程度与给药剂量负相关,A、B、C组滴度分别增加6.2、2.7、9 log10。
  • 感染后24小时肺匀浆中噬菌体耐药细菌亚群随治疗剂量增加,A、B、C组分别为30%、74%、91%。
  • 耐药突变体对环丙沙星敏感性增加、蹭行运动受损、蓝绿色色素产生减少。
  • 随着PEV31治疗剂量增加,炎症细胞因子(IL-1β、IL-6和TNF-α)表达受到抑制。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Inhaled phage therapy has been revisited as a potential treatment option for respiratory infections caused by multidrug-resistant Pseudomonas aeruginosa; however, there is a distinct gap in understanding the dose-response effect. The aim of this study was to investigate the dose-response effect of Pseudomonas-targeting phage PEV31 delivered by the pulmonary route in a mouse lung infection model. METHODS: Neutropenic BALB/c mice were infected with multidrug-resistant P. aeruginosa (2 × 104 colony-forming units) through the intratracheal route and then treated with PEV31 at three different doses of 7.5 × 104 (Group A), 5 × 106 (Group B), and 5 × 108 (Group C) plaque-forming units, or phosphate-buffered saline at 2 hours postinoculation. Mice (n = 5-7) were euthanized at 2 hours and 24 hours postinfection, and lungs, kidneys, spleen, liver, bronchoalveolar lavage fluid, and blood were collected for bacteria and phage enumeration. RESULTS: At 24 hours postinfection, all phage-treated groups exhibited a significant reduction in pulmonary bacterial load by 1.3-1.9 log10, independent of the delivered phage dose. The extent of phage replication was negatively correlated with the dose administered, with log10 titre increases of 6.2, 2.7, and 9 for Groups A, B, and C, respectively. Phage-resistant bacterial subpopulations in the lung homogenate samples harvested at 24 hours postinfection increased with the treatment dose (i.e. 30%, 74%, and 91% in respective Groups A-C). However, the mutants showed increased susceptibility to ciprofloxacin, impaired twitching motility, and reduced blue-green pigment production. The expression of the inflammatory cytokines (IL-1ß and IL-6, and TNF-α) was suppressed with increasing PEV31 treatment dose. DISCUSSION: This study provides the dose-response effect of inhaled phage therapy that may guide dose selection for treating P. aeruginosa respiratory infections in humans.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Chang RYK, Chow MYT, Wang Y, et al. The effects of different doses of inhaled bacteriophage therapy for Pseudomonas aeruginosa pulmonary infections in mice. Clin Microbiol Infect. 2022. PMID: 35123053. doi:10.1016/j.cmi.2022.01.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。